Efficacy study of Sygnis's G-CSF in stroke under way
This article was originally published in Scrip
The German company Sygnis Pharma expects clinical data from its Phase II study of its G-CSF product, AX200, in acute ischaemic stroke, to be available in the middle of 2011.
You may also be interested in...
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.